Matthias J. Schnell, PhD
Chair, Department of Microbiology & Immunology
Dr. V. Watson Pugh & Frances Plimpton Pugh Professor in Microbiology & Immunology
Director, Jefferson Center for Vaccines & Pandemic Preparedness
Contact
233 South Tenth Street
Bluemle Life Sciences Building, Room 531
Philadelphia, PA 19107-5541
215-503-4634
215-503-5393 fax
Featured Links
Matthias J. Schnell, PhD
Chair, Department of Microbiology & Immunology
Dr. V. Watson Pugh & Frances Plimpton Pugh Professor in Microbiology & Immunology
Director, Jefferson Center for Vaccines & Pandemic Preparedness
Expertise & Research Interests
Research interest: The research interest of the laboratory is focus on two areas: 1) vaccine development; and 2) viral pathogenesis.
Vaccines against emerging viral diseases: Rhabdovirus-based vectors as vaccines against other infectious diseases.
- Rabies virus (RABV) based vaccines are promising as both live and killed vaccines against infectious disease. This is based on the finding that RABV vectors are highly immunogenic and combine a necessary vaccine with limited financial resources for development (such as several hemorrhagic fever viruses) with a safe, approved, and financially practical vaccine (rabies).
- Using different molecular and immunological approaches, we perform detailed studies of highly attenuated RABV expressing and incorporating immunogenic proteins of emerging infectious diseases. Most advanced is the development of our filovirus (e.g. Ebola Virus (EBOV), Sudan virus (SUDV) and Marburg virus (MARV)) vaccine. Protection studies in NHP were promising and the vaccine will enter the clinic soon.
- In the pre-clinical phase of development are novel vaccines against Hendra virus, Nipah virus, Lassa virus, Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) and Zika virus. Toward this approach, we study the efficacy of RABV as well as a Vesicular stomatitis virus (VSV)-based vaccine platform against these emergent and highly pathogenic viruses. The goal is the development of this vaccine platform not only for human use but also to immunize animals to break the transmission cycle of these zoonotic diseases.
- Development of safer and more potent vaccines for wildlife and human rabies.
- Development of novel vaccines against lyssaviruses (rabies-related viruses) from which the current rabies vaccine does not protect.
Viral pathogenicity: We are interested in a detailed understanding of the biochemistry, molecular biology and immunology of rabies virus and its interaction with the infected host. The molecular mechanism of rabies virus pathogenesis is not well understood and our research analyses the different functions the rhabdoviral proteins (e.g. rabies virus) and their interaction with cellular host proteins.
Education
PhD, Virology, University of Stuttgart-Hohenheim & Federal Research Center for Virus Diseases of Animals, Tuebingen, Germany
BS/MS, Biology, University of Stuttgart-Hohenheim, Stuttgart, Germany
Fellowship
Yale University, New Haven, CT
Publications
- Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease
- Toward the Development of a Pan-Lyssavirus Vaccine
- The Development of a Rabies Virus-Vectored Vaccine against Borrelia burgdorferi, Targeting BBI39
- GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus
- Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge